Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06716580 · ClinicalTrials.gov registry record · NA

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

A NA study of Lung Cancer and EGFR Gene Mutation, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
1,000
Enrollment target
6
Study locations

NCT06716580 is a NA study of Lung Cancer and EGFR Gene Mutation that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,000 participants, roughly in line with the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target. The trial reports 6 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06716580, a NA study of Lung Cancer and EGFR Gene Mutation, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
1,000 participants
Enrollment target
6
Study locations

Study Summary

This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay

Conditions Studied

Lung Cancer EGFR Gene Mutation

Interventions

  • DEVICE Circulating Tumor DNA (ctDNA) Assay

Study Locations (6)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston
  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute at Steward St. Elizabeth's - Brighton
  • Dana-Farber Cancer Instiute Merrimack Valley - Methuen
  • Dana-Farber Cancer Institute South Shore - South Weymouth

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2025-04-01
Est. Completion 2030-09-01
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06716580

The ClinicalTrials.gov registry entry for NCT06716580 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Circulating Tumor DNA (ctDNA) Assay is the first listed.

NCT06716580 reports 6 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06716580 about?

NCT06716580 is a clinical study titled "EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations". This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DN...

What is the current status of trial NCT06716580?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2025-04-01. Estimated completion is 2030-09-01.

What conditions does trial NCT06716580 study?

This clinical trial studies the following conditions: Lung Cancer, EGFR Gene Mutation.

What interventions are being tested in trial NCT06716580?

The interventions under investigation include: Circulating Tumor DNA (ctDNA) Assay (DEVICE).

Who is sponsoring clinical trial NCT06716580?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06716580 being conducted?

This trial has 6 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

EGFR Gene Mutation

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.